Key Takeaway: Cognition Therapeutics has announced positive topline results from its Phase 2 trial for a drug aimed at treating dementia with Lewy bodies. The trial results suggest that the drug may offer significant benefits, marking a hopeful advancement in the treatment of this condition.
Price reaction · baseline $0.58 (2024-12-18 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
+9.3%
day 1
+8.6%
day 3 · peak
+11.7%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics' drug shows encouraging results.
The Phase 2 trial indicates potential benefits for dementia with Lewy bodies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What are the results of Cognition Therapeutics' Phase 2 trial?
The Phase 2 trial results indicate encouraging outcomes for the drug targeting dementia with Lewy bodies.
What condition is Cognition Therapeutics' drug targeting?
The drug is aimed at treating dementia with Lewy bodies.